Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Angiomatoid Fibrous Histiocytoma
Epithelioid Sarcoma
Intimal Sarcoma
Malignant Skin Granular Cell Tumor
Malignant Triton Tumor
Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Atypical Fibroxanthoma
Clear Cell Sarcoma of Soft Tissue
Low Grade Myofibroblastic Sarcoma
Myxofibrosarcoma

Interventions: Drug: Pazopanib
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Pazopanib Hydrochloride
Drug: Ifosfamide
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2014-07-03

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 140

Registration Number: NCT02180867

Locations: 🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
AdventHealth Orlando, Orlando, Florida, United States

and more 379 locations

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Phase 3

Terminated

Conditions: Recurrent Nasopharynx Carcinoma

Interventions: Drug: Etoposide phosphate
Drug: Carboplatin
Drug: Ifosfamide
Procedure: Autologous Stem Cell Transplantation

First Posted Date: 2014-05-13

Last Posted Date: 2019-06-24

Lead Sponsor: University of Florida

Target Recruit Count: 1

Registration Number: NCT02137096

Locations: 🇺🇸
UF Health Shands Hospital, Gainesville, Florida, United States

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

First Posted Date: 2014-04-14

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 847

Registration Number: NCT02112916

Locations: 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸
UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺
Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia

and more 209 locations

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Radiation: Radiation Therapy
Drug: Dexamethasone
Drug: Etoposide phosphate
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin

First Posted Date: 2014-04-08

Last Posted Date: 2024-06-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT02106988

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Phase 2

Conditions: Sinonasal Tumors

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Etoposide
Drug: Adriamycin
Drug: Ifosfamide
Drug: Leucovorin
Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Radiation: Radiotherapy - Patients not needing ENI
Radiation: Radiotherapy - Patients needing curative neck irradiation

First Posted Date: 2014-03-28

Last Posted Date: 2023-03-13

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 41

Registration Number: NCT02099175

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
🇮🇹
Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹
IRCCS Policlinico San Matteo, Pavia, PV, Italy

and more 2 locations

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Phase 2

Conditions: Unresectable Sinonasal Tumors

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: 5-fluorouracil
Drug: Etoposide
Drug: Adriamycin
Drug: Ifosfamide
Drug: Leucovorin
Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)
Radiation: Radiotherapy - Patients not needing ENI
Radiation: Radiotherapy - Patients needing curative neck irradiation

First Posted Date: 2014-03-28

Last Posted Date: 2023-03-13

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 27

Registration Number: NCT02099188

Locations: 🇮🇹
Presidio Ospedaliero Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹
IRCCS Policlinico San Matteo, Pavia, PV, Italy
🇮🇹
A.O. Ospedale di Circolo e Fondazione Macchi, Varese, VA, Italy

and more 2 locations

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Pleomorphic Rhabdomyosarcoma
Stage III Adult Soft Tissue Sarcoma AJCC v7
Stage IIB Adult Soft Tissue Sarcoma AJCC v7
Stage IV Adult Soft Tissue Sarcoma AJCC v7

Interventions: Drug: Epirubicin Hydrochloride
Radiation: External Beam Radiation Therapy
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2014-01-31

Last Posted Date: 2022-03-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02050919

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Phase 1

Completed

Conditions: B-Cell Malignancies

Interventions: Drug: Parsaclisib
Drug: Itacitinib
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2013-12-23

Last Posted Date: 2023-09-28

Lead Sponsor: Incyte Corporation

Target Recruit Count: 88

Registration Number: NCT02018861

Locations: 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
🇺🇸
Nyu Langone Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

and more 4 locations

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

Interventions: Drug: Crizotinib
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ifosfamide
Drug: Methotrexate

First Posted Date: 2013-11-08

Last Posted Date: 2024-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 137

Registration Number: NCT01979536

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States

and more 151 locations

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Stage I Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
CD20 Positive
Stage IV Diffuse Large B-Cell Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Carfilzomib
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2013-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01959698

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy